Insider · CIK 0001837016
Dean Y Li
Files at MRK (Merck & Co., Inc.), RXRX (RECURSION PHARMACEUTICALS, INC.). First filing Jan 11, 2024, latest Feb 10, 2026.
In brief
Dean Y Li files SEC Form 4 as director and officer at MRK (Merck & Co., Inc.), and also at RXRX (RECURSION PHARMACEUTICALS, INC.). Since Jan 11, 2024, Dean Y Li has reported 0 open-market buys worth $0 and 4 open-market sells worth $5.2M, the latest filed on Feb 10, 2026.
A track record needs three past buys with six months of prices behind them; Dean Y Li has 0, so none is measured yet.
The newest scored trade: sold $1.2M of MRK on Feb 10, 2026, filed Feb 10, 2026, scored 60 (notable). In the last 12 months: 0 buys worth $0 and 2 sells worth $3.0M.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
MRK: Merck & Co., Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
RXRX: RECURSION PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 60Notable | Merck & Co., Inc. | $1.2M 10,235 shares | -10% | +64% from low-4% from high | |
| 45Moderate | Merck & Co., Inc. | $1.8M 15,087 shares | -13% | +66% from low0% from high | |
| 45Moderate | Merck & Co., Inc. | $1.8M 14,702 shares | -24% | +26% from low-2% from high | |
| 26Weak | RECURSION PHARMACEUTICALS, INC. | $396k 29,000 shares | -6% | +194% from low-16% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 10, 2026 | MRK MERCK & CO., INC. | 10,235 0.00% of outstanding | $1.2M | Feb 10, 2026 | $1.8M |
| Feb 4, 2026 | MRK MERCK & CO., INC. | 15,087 0.00% of outstanding | $1.8M | Feb 4, 2026 | none |
| Feb 9, 2024 | MRK MERCK & CO. INC. | 14,702 0.00% of outstanding | $1.8M | Feb 9, 2024 | none |
| Jan 9, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | 29,000 0.01% of outstanding | $397k | Jan 9, 2024 | none |
| Jan 9, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | 29,000 0.01% of outstanding | $396k | Jan 9, 2024 | none |
Transactions
Every row this insider has filed, 33 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +3,378 | $0.00 | $0 | 1,476,707 | 12 d ago |
| Jul 1, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +3,747 | $0.00 | $0 | 1,473,329 | Jul 2, 2026 |
| Jun 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +88,424 | $0.00 | $0 | 1,469,582 | Jun 22, 2026 |
| May 5, 2026 | MRK Merck & Co., Inc. | AGrant or award Restricted Stock Unitderivative | +19,885 | $0.00 | $0 | 19,885 | May 7, 2026 |
| May 5, 2026 | MRK Merck & Co., Inc. | AGrant or award Stock Option (Right to Buy)derivative | +58,207 | $0.00 | $0 | 58,207 | May 7, 2026 |
| Apr 29, 2026 | MRK Merck & Co., Inc. | MOption exercise Common Stock | +4,722 | $110.03 | $520k | 96,757 | May 1, 2026 |
| Apr 29, 2026 | MRK Merck & Co., Inc. | FTax withholding Common Stock | -2,326 | $110.03 | $256k | 94,431 | May 1, 2026 |
| Apr 29, 2026 | MRK Merck & Co., Inc. | MOption exercise Restricted Stock Unitderivative | -4,722 | $0.00 | $0 | 9,444 | May 1, 2026 |
| Apr 1, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +3,268 | $0.00 | $0 | 1,244,177 | Apr 2, 2026 |
| Feb 10, 2026 | MRK Merck & Co., Inc. | SOpen-market sale Common Stock | -10,235 | $117.52 | $1.2M | 92,035 | Feb 10, 2026 |
| Feb 4, 2026 | MRK Merck & Co., Inc. | MOption exercise Common Stock | +15,087 | $56.04 | $845k | 117,357 | Feb 6, 2026 |
| Feb 4, 2026 | MRK Merck & Co., Inc. | SOpen-market sale Common Stock | -15,087 | $118.77 | $1.8M | 102,270 | Feb 6, 2026 |
| Feb 4, 2026 | MRK Merck & Co., Inc. | MOption exercise Stock Option (Right to Buy)derivative | -15,087 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Jan 26, 2026 | MRK Merck & Co., Inc. | AGrant or award Common Stock | +20,469 | $107.40 | $2.2M | 102,270 | Jan 28, 2026 |
| Jan 2, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +2,381 | $0.00 | $0 | 1,240,909 | Jan 6, 2026 |
| Oct 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +1,961 | $0.00 | $0 | 1,238,528 | Oct 3, 2025 |
| Jul 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +1,949 | $0.00 | $0 | 1,236,567 | Jul 3, 2025 |
| Jun 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +22,016 | $0.00 | $0 | 1,234,618 | Jun 23, 2025 |
| Jun 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +44,031 | $0.00 | $0 | 44,031 | Jun 23, 2025 |
| Apr 29, 2025 | MRK Merck & Co., Inc. | AGrant or award Restricted Stock Unitderivative | +14,166 | $0.00 | $0 | 14,166 | May 1, 2025 |
| Apr 29, 2025 | MRK Merck & Co., Inc. | AGrant or award Stock Option (Right to Buy)derivative | +64,481 | $0.00 | $0 | 64,481 | May 1, 2025 |
| Apr 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +2,268 | $0.00 | $0 | 79,618 | Apr 3, 2025 |
| Jun 3, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +13,097 | $0.00 | $0 | 72,186 | Jun 5, 2024 |
| Jun 3, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +26,193 | $0.00 | $0 | 26,193 | Jun 5, 2024 |
| Apr 30, 2024 | MRK Merck & Co., Inc. | AGrant or award Stock Option (Right to Buy)derivative | +65,625 | $0.00 | $0 | 65,625 | May 2, 2024 |
| Apr 1, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +1,267 | $0.00 | $0 | 59,089 | Apr 3, 2024 |
| Feb 9, 2024 | MRK Merck & Co., Inc. | MOption exercise Common Stock | +14,702 | $62.07 | $913k | 60,944 | Feb 12, 2024 |
| Feb 9, 2024 | MRK Merck & Co., Inc. | SOpen-market sale Common Stock | -14,702 | $125.50 | $1.8M | 46,242 | Feb 12, 2024 |
| Feb 9, 2024 | MRK Merck & Co., Inc. | MOption exercise Stock Option (Right to Buy)derivative | -14,702 | $0.00 | $0 | 0 | Feb 12, 2024 |
| Jan 22, 2024 | MRK Merck & Co., Inc. | AGrant or award Common Stock | +25,760 | $119.43 | $3.1M | 46,242 | Jan 24, 2024 |
| Jan 9, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stockindirect: By Dean Y. Li 2021 Family Trust10b5-1 | -28,038 | $13.65 | $383k | 421,962 | Jan 11, 2024 |
| Jan 9, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | SOpen-market sale Class A Common Stockindirect: By Dean Y. Li 2021 Family Trust10b5-1 | -962 | $14.03 | $13k | 421,000 | Jan 11, 2024 |
| Jan 2, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +1,203 | $0.00 | $0 | 1,327,618 | Jan 4, 2024 |
Questions about Dean Y Li
Answered from the filings on this page, as of the latest one.
Is Dean Y Li buying or selling?
In the last 12 months Dean Y Li reported 0 open-market buys worth $0 and 2 open-market sells worth $3.0M on SEC Form 4; the latest was sold $1.2M of MRK on Feb 10, 2026. Grants, option exercises and tax withholding are not counted.
How did Dean Y Li's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dean Y Li has 0.
Where does Dean Y Li file Form 4?
Dean Y Li has filed Form 4 at MRK (Merck & Co., Inc.) as Executive VP & President, MRL; RXRX (RECURSION PHARMACEUTICALS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.